Finanzen von OncoCyte Corp (OCX)OCXOncoCyte Corp

OncoCyte Corp (OCX) generates its revenue primarily from Pharma Services, which accounts for 100.0% of total sales, equivalent to $104.00K. Understanding this concentration is critical for investors evaluating how OCX navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, OncoCyte Corp maintains a gross margin of 61.97%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -276.89%, while the net margin is -312.02%. These profitability ratios, combined with a Return on Equity (ROE) of -534.37%, provide a clear picture of how effectively OCX converts its operational activities into shareholder value.

In the context of the broader market, OCX competes directly with industry leaders such as ZURA and ELUT. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, OCX's gross margin of 61.97% stands against ZURA's N/A and ELUT's 57.87%. Such benchmarking helps identify whether OncoCyte Corp is trading at a premium or discount relative to its financial performance.